Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.
Why was this year's APA Annual Meeting historic? H. Steven Moffic, MD, shares his thoughts.
How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.
The APA Annual Meeting: a valuable career opportunity.
At the APA Annual Meeting, John Luo, MD, discussed the importance of managing your online reputation and privacy in today's digital landscape for future opportunities.
Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.
Although there are topics in psychiatry that not exciting, Dr Ghaemi sees plenty of opportunities.
Mena Mirhom, MD, the Psychiatric Times Media & Psychiatry Section Editor, discusses media training for psychiatry fellows, enhancing their skills to effectively communicate and combat misinformation.
Dr Nassir Ghaemi explores the long-term effects and safety of serotonin reuptake inhibitors, revealing benefits and potential risks.
John J. Miller, MD, discusses the updates to the delirium practice guidelines with Mark A. Oldham, MD
A nonprofit aims to support clinicians and patients with insurance coverage for evidence-based medicine.
Badr Ratnakaran, MBBS, highlights the growing loneliness epidemic and emphasizes its severe impact on mental and physical health at the 2025 APA Annual Meeting.
Resilience: how does it improve overall health? Helen Lavretsky, MD, shared her thoughts at the 2025 APA Annual Meeting.
Attendees at the 2025 APA Annual Meeting are excited to connect with peers and experts, exploring lifestyle medicine and networking opportunities for career growth.
Mental health professionals recognize the profound impact of climate change on anxiety, depression, and overall well-being, urging proactive support for affected patients, says one APA attendee.
Can GLP-1 agonists support patients on antipsychotics? Amir Meftah, MD, and colleagues explore its use.
Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.
At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.
Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.
Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.
What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.
"I feel I’ve known him a long time, familiar as red in the maple outside or the smell of leather on my father’s skin..."
Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.
Let's take another look at the connection between motherhood and mental health.
Hypersomnias are a complex set of sleep disorders. Proper sleep evaluations are crucial for accurate diagnosis.
